A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
BeiGene
Kura Oncology, Inc.
The Thai Lymphoma Study Group
UNICANCER
Stanford University
University of Nebraska
University of Nebraska
University of Nebraska
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Chonnam National University Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Northwestern University
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Mayo Clinic
University of Chicago
Swiss Cancer Institute
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
Ruijin Hospital
National Cancer Institute (NCI)
ChineseAMS
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Wake Forest University Health Sciences
University of Washington
University of Washington
Fred Hutchinson Cancer Center